Lead Sponsor

Arrowhead Pharmaceuticals

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Based on medical history, evidence of triglycerides (TG) ≥ 500 mg/dL and ≤ 4000 mg/dL at Screening
•Fasting TG ≥ 500 mg/dL at Screening
•Willing to follow diet counseling per Investigator judgment based on local standard of care
•Women of childbearing potential must have a negative pregnancy test, cannot be breastfeeding, and must be willing to use contraception
•Willing to provide written informed consent and to comply with study requirements

•Active pancreatitis within 12 weeks prior to first dose
•Any planned bariatric surgery or similar procedures to induce weight loss from consent to end of study
•Acute coronary syndrome event within 24 weeks of first dose
•Major surgery within 12 weeks of first dose
•Planned coronary intervention (e.g., stent placement or heart bypass) or any non-cardiac major surgical procedure throughout the study
•Uncontrolled hypertension
•Human immunodeficiency virus (HIV) infection, seropositive for Hepatitis B (HBV), seropositive for Hepatitis C (HCV)
•Uncontrolled hypothyroidism or hyperthyroidism
•Hemorrhagic stroke within 24 weeks of first dose
•Malignancy within the last 2 years prior to date of consent requiring systemic treatment (some exceptions apply)